The November 2011 issue of Drug Safety Update from the MHRA features an article about yellow card reports that have made a difference, with a particular emphasis on high dose rosuvastatin being associated with an increased incidence of rhabdomyolisis. The article states that by February 2004, 5 reports of rhabdomyolysis with rosuvastatin had been reported, and the rosuvastatin dose was reported to be at 40 mg or higher in four of the 5 reports received. Furthermore, the reporting rate (taking prescribing data into account) was higher than expected relative to historical data with other statins.